Geneva, Switzerland, April 21, 2020–7:30am CEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple sclerosis , today announcesthe appointment of the experienced medical and industry professional Prof. David Leppert, MD and Professor of Neurology, as Chief Medical Officer.
For more information, http://www.geneuro.com/data/news/GeNeuro-PR-CMO-appointment-EN.pdf
